

Ally Therapeutics

Ally Therapeutics is a gene therapy company spun out of Harvard. Ally's vision is to develop intrinsically less immunogenic gene therapies to enable treatment of broader populations of patients. Ally's first technology, which blocks an early innate immune sensor for AAV gene therapy vectors, has reached proof-of-concept across several routes of administration in experiments using human cells, mice, pigs, and monkeys. Ally is pursuing a hybrid product-platform business model, combining an in-house pipeline of novel therapies and partnering with companies pursuing complementary markets.

31 July 2019. Ally secured seed finance from ARCH Venture Partners, Alta Partners and UCB Ventures to advance its novel gene therapy platform.